Pascal Touchon, Atara Biotherapeutics CEO

EC ap­proves first al­lo­gene­ic T cell ther­a­py for rare post-trans­plant com­pli­ca­tion

The Eu­ro­pean Com­mis­sion signed off on the con­ti­nent’s first al­lo­gene­ic T cell ther­a­py Mon­day. And for its mak­er Atara Bio­ther­a­peu­tics, the ap­proval marks the biotech’s first ap­proved ther­a­py.

Ebval­lo, made by Atara Bio­ther­a­peu­tics, is now ap­proved by the EMA for mar­ket­ing au­tho­riza­tion for a spe­cif­ic sub­group of pa­tients with post-trans­plant lym­pho­pro­lif­er­a­tive dis­ease who are pos­i­tive for Ep­stein-Barr virus. The dis­ease, al­so known as EBV+ PTLD for short, is a rare com­pli­ca­tion that can oc­cur af­ter a sol­id or­gan or hematopoi­et­ic stem cell trans­plant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.